As part of the contract, DSM will develop and manufacture Paranta’s lead recombinant human protein, follistatin.
The agreement also represents DSM’s collaboration with an Australian customer at their Brisbane facility.
DSM Pharmaceutical Products Alexander CEO Wessels said, "Working with Paranta is an important milestone for DSM to support the local client base directly from our facility in Australia, expanding our presence in global regions.”
Paranta Biosciences CEO Ross Barrow said Follistatin has been shown to have great potential in treating a wide range of inflammatory and fibrotic respiratory diseases.
"Our selection of DSM as Paranta’s biologics manufacturing partner is the culmination of an extensive global search process spanning more than nine months," Barrow added.